The following table presents revenue by category:


	Three Months Ended September 30,										Six Months Ended September 30,
	2023					2022					2023					2022
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)										(in thousands, except percentages)
Point in Time (1)
PGS	$	34,202		68	%	$	40,110		53	%	$	65,961		59	%	$	79,800		57	%
Telehealth		6,872		14	%		9,171		12	%		15,157		14	%		18,532		13	%
Consumer services		41,074		82	%		49,281		65	%		81,118		73	%		98,332		70	%
Research services		—		—			—		—			2,353		2	%		—		—
Total	$	41,074		82	%	$	49,281		65	%	$	83,471		75	%	$	98,332		70	%

Over Time (1)
PGS	$	5,400		11	%	$	4,731		7	%	$	10,670		10	%	$	9,216		6	%
Telehealth		2,184		4	%		2,497		3	%		4,423		4	%		5,020		4	%
Consumer services		7,584		15	%		7,228		10	%		15,093		14	%		14,236		10	%
Research services		1,341		3	%		19,150		25	%		12,299		11	%		27,604		20	%
Total	$	8,925		18	%	$	26,378		35	%	$	27,392		25	%	$	41,840		30	%

Revenue by Category (1)
PGS	$	39,602		79	%	$	44,841		60	%	$	76,631		69	%	$	89,016		63	%
Telehealth		9,056		18	%		11,668		15	%		19,580		18	%		23,552		17	%
Consumer services		48,658		97	%		56,509		75	%		96,211		87	%		112,568		80	%
Research services		1,341		3	%		19,150		25	%		14,652		13	%		27,604		20	%
Total	$	49,999		100	%	$	75,659		100	%	$	110,863		100	%	$	140,172		100	%

(1)

There was no Therapeutics revenue for the three and six months ended September 30, 2023 and 2022.

The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered:


	Three Months Ended September 30,										Six Months Ended September 30,
	2023					2022					2023					2022
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)										(in thousands, except percentages)
United States	$	42,185		84	%	$	52,546		69	%	$	85,511		77	%	$	100,655		72	%
United Kingdom		4,163		8	%		19,030		25	%		18,518		17	%		31,004		22	%
Canada		2,558		5	%		2,839		4	%		4,728		4	%		5,878		4	%
Other regions		1,093		3	%		1,244		2	%		2,106		2	%		2,635		2	%
Total	$	49,999		100	%	$	75,659		100	%	$	110,863		100	%	$	140,172		100	%

The Company sells through multiple channels, including direct-to-consumer via the Company’s website and through online retailers. If the customer does not return the Kit for processing, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. The Company recognized breakage revenue from unreturned Kits of $4.3 million and $6.0 million for the three months ended September 30, 2023 and 2022, respectively, and $8.9 million and $11.0 million for the six months ended September 30, 2023 and 2022, respectively.

Accounts receivable are recorded when the right to consideration becomes unconditional. Contract assets include amounts associated with contractual rights related to consideration for performance obligations and are included in prepaid expenses and other current assets on the condensed consolidated balance sheets. The amount of contract assets was immaterial as of September 30, 2023 and March 31, 2023.

Contract liabilities consist of deferred revenue. As of September 30, 2023 and March 31, 2023, deferred revenue for consumer services was $39.2 million and $48.6 million, respectively. Of the $48.6 million of deferred revenue for consumer services as of March 31, 2023, the Company recognized $8.9 million and $31.4 million as revenue during the three and six months ended September 30, 2023, respectively.

As of September 30, 2023 and March 31, 2023, deferred revenue for research services was $1.1 million and $14.0 million, respectively. As of March 31, 2023, deferred revenue for research services included $11.8 million of related party deferred revenue. There was no related party deferred revenue as of September 30, 2023. Of the $14.0 million of deferred revenue for research services as of March 31, 2023, the Company recognized $1.2 million and $13.6 million as revenue during the three and six months ended September 30, 2023, respectively, which included related party revenue amounts of $1.1 million and $11.8 million, respectively.

The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that are expected to be billed and recognized as revenue in future periods. The Company has utilized the practical expedient available under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”) to not disclose the value of unsatisfied performance obligations for PGS and telehealth as those contracts have an expected length of one year or less. As of September 30, 2023, the aggregate amount of the transaction price allocated to remaining performance obligations for research services was $2.9 million. The Company expects to recognize revenue of approximately 75% of this amount over the next 12 months and the remainder thereafter. During the three and six months ended September 30, 2023 and 2022, the Company did not recognize any revenue for performance obligations satisfied in prior periods.